World Pharma News

Syndicate content World Pharma News
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements
Updated: 2 hours 26 min ago

AWS announces strategic collaboration with Novartis to accelerate digital transformation of its business operations

Wed, 12/04/2019 - 16:00
Today, Amazon Web Services, Inc. (AWS), an company (NASDAQ: AMZN), announced a multi-year strategic collaboration with Novartis to reimagine this leading pharmaceutical company's core pharmaceutical manufacturing, supply chain, and delivery operations using AWS's portfolio of cloud services.

The gut may be involved in the development of multiple sclerosis

Wed, 12/04/2019 - 11:00
It is incompletely understood which factors in patients with multiple sclerosis (MS) act as a trigger for the immune system to attack the brain and spinal cord. A potential factor is described by a research team in the journal Proceedings of the National Academy of Sciences, PNAS. The medical researchers used an animal model to show that the protein Smad7 mobilises immune cells in the intestines which, in turn, trigger inflammation in the central nervous system.

Olaparib becomes first gene-targeted medicine to show benefits in prostate cancer

Tue, 12/03/2019 - 13:00
A pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour growth in some men with advanced prostate cancer, a new clinical trial shows. The phase II trial found that over 80 per cent of men with prostate cancer whose tumours had mutations in the BRCA genes responded well to treatment with the targeted drug olaparib.

AstraZeneca divests rights to Seroquel and Seroquel XR in the US and Canada

Tue, 12/03/2019 - 11:00
AstraZeneca has agreed to sell the commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in the US and Canada to Cheplapharm Arzneimittel GmbH (Cheplapharm). Seroquel and Seroquel XR, used primarily to treat schizophrenia and bipolar disorder, have lost their compound patent protection in the US and Canada.

FDA approves Pfizer's biosimilar, ABRILADA™ (adalimumab-afzb) for multiple inflammatory conditions

Mon, 12/02/2019 - 13:00
Pfizer Inc. (NYSE: PFE) announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),(1) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.(2)

Investigational drugs reduce risk of death from Ebola virus disease

Mon, 12/02/2019 - 11:00
The investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease (EVD) compared to the investigational treatment ZMapp, according to published results from a clinical trial conducted in the Democratic Republic of the Congo (DRC). The new report also shows that early diagnosis and treatment are associated with an increased likelihood of survival from EVD.

Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer

Fri, 11/29/2019 - 11:00
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC).

Bayer selects Pharmaron as partner organization

Thu, 11/28/2019 - 13:00
Bayer and Pharmaron have entered into a global collaboration agreement to develop new molecular entities for veterinary medicines. Under the collaboration, Bayer will fully leverage Pharmaron's Chemistry, Manufacturing and Controls (CMC) service platform.

Pharmacist-led interventions may help prevent cardiovascular disease

Thu, 11/28/2019 - 11:00
With their expertise in the safe and effective use of medications, pharmacists can help in the management of chronic diseases. A review and analysis published in the British Journal of Clinical Pharmacology indicates that initiatives - such as patient education, medication review, and physical assessments - led by pharmacists can make important contributions to the prevention of cardiovascular disease.

FDA grants priority review to Roche’s risdiplam for spinal muscular atrophy

Wed, 11/27/2019 - 13:00
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for risdiplam, an investigational survival motor neuron-2 (SMN-2) splicing modifier for SMA. Risdiplam is designed to increase and sustain SMN protein levels both throughout the central nervous system and peripheral tissues of the body.

A protein tag to study the immune system

Wed, 11/27/2019 - 11:00
Researchers from VIB-UGent Center for Medical Biotechnology, University of Iowa (USA) and other collaborators, developed a novel approach to better understand a basic defense mechanism of our immune system. Central is ISG15, a small protein with a role in the immune system. With the newly developed method, scientists can now identify and study proteins tagged with ISG15, allowing them to

Excellent market conditions at largest ever CPhI Worldwide bodes well for global pharma in 2020

Tue, 11/26/2019 - 13:00
5 - 7 November 2019, Frankfurt, Germany.
CPhI Worldwide closed its doors on its landmark 30th edition at the Messe Frankfurt, with pre-audit figures showcasing a record total attendance of 48,961 - 84% of which were international. This year's event saw a number of key indicators pointing to a strong year ahead for pharma in 2020. CPhI Worldwide is widely recognised as a barometer of pharma's overall health - with the addition of

SMi Group's 12th Annual Conference and Exhibition: Pre-Filled Syringes and Injectable Drug Devices 2020

Tue, 11/26/2019 - 11:00
15 - 16 January 2020, London, UK.
SMi are pleased to present the 12th Annual Pre-Filled Syringes and Injectable Drug Devices conference in London. As Europe's leading Pre-Filled Syringes conference, the 2020 event will assess innovations in device engineering and components, enhancement of human factors, and optimizing packaging and containment.

FDA approves novel treatment to target abnormality in sickle cell disease

Tue, 11/26/2019 - 00:00
Today, the U.S. Food and Drug Administration granted accelerated approval to Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.

"Today's approval provides additional hope to the 100,000 people in the U.S., and the more than 20 million globally, who live with this debilitating blood disorder," said Acting FDA Commissioner Adm. Brett P. Giroir, M.D.

Industry executives: Profits drive rising prices for MS drugs

Mon, 11/25/2019 - 11:00
U.S. Medicare patients with multiple sclerosis often pay, on average, nearly $7,000 out of pocket to treat their condition each year. And, even though drug companies have provided no new treatment breakthroughs, the price of these disease-modifying medications is rising by 10% to 15% each year for the past decade.

SMi's 4th Annual 3D Cell Culture

Fri, 11/22/2019 - 11:00
19 - 20 February 2020, London, UK.
Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues, drug discovery, predictivity and validation, and safety and toxicity.

Amgen completes acquisition of Otezla® (apremilast)

Thu, 11/21/2019 - 13:00
Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for moderate-to-severe plaque psoriasis and psoriatic arthritis. Otezla was acquired from Celgene Corporation (NASDAQ:CELG) in connection with its previously announced merger with Bristol-Myers Squibb Company (NYSE:BMY), which was completed on Nov. 20.

Bristol-Myers Squibb completes acquisition of Celgene, creating a leading biopharma company

Thu, 11/21/2019 - 11:00
Bristol-Myers Squibb Company (NYSE:BMY) has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders.

FDA approves first treatment for inherited rare disease

Wed, 11/20/2019 - 18:00
Today, the U.S. Food and Drug Administration granted approval to Givlaari (givosiran) for the treatment of adult patients with acute hepatic porphyria, a genetic disorder resulting in the buildup of toxic porphyrin molecules which are formed during the production of heme (which helps bind oxygen in the blood).

Artificial Intelligence algorithm can learn the laws of quantum mechanics and speed up drug delivery

Wed, 11/20/2019 - 11:00
Artificial Intelligence can be used to predict molecular wave functions and the electronic properties of molecules. This innovative AI method developed by a team of researchers at the University of Warwick, the Technical University of Berlin and the University of Luxembourg, could be used to speed-up the design of drug molecules or new materials.